韓曉東 孟松樹 程為 孫喆 倪靜 張?jiān)骑w 林景榮 宋智琦
·論著·
芹菜素抑制人惡性黑素瘤細(xì)胞株增殖及侵襲的研究
韓曉東 孟松樹 程為 孫喆 倪靜 張?jiān)骑w 林景榮 宋智琦
目的 研究芹菜素對(duì)惡性黑素瘤體外抑制作用及其分子機(jī)制。方法 將人惡性黑素瘤細(xì)胞株A375和C8161分為實(shí)驗(yàn)組和對(duì)照組,實(shí)驗(yàn)組經(jīng)不同濃度芹菜素處理一定時(shí)間,對(duì)照組采用二甲基亞砜處理。采用噻唑藍(lán)(MTT)法檢測(cè)A375和C8161細(xì)胞的增殖,劃痕法檢測(cè)細(xì)胞遷移。Matrigel侵襲實(shí)驗(yàn)檢測(cè)細(xì)胞侵襲性,掃描電鏡觀察細(xì)胞樹突形態(tài),膜聯(lián)蛋白V/碘化丙錠(Annexin-V/PI)法檢測(cè)細(xì)胞凋亡,PI單染法檢測(cè)細(xì)胞周期,Western印跡檢測(cè)細(xì)胞凋亡及細(xì)胞外信號(hào)調(diào)節(jié)激酶通路相關(guān)蛋白的表達(dá)。結(jié)果 MTT顯示,芹菜素在10~40 mg/L濃度范圍內(nèi)對(duì)A375和C8161細(xì)胞抑制作用呈量效關(guān)系,在0~48 h呈時(shí)效關(guān)系,與對(duì)照組相比差異有統(tǒng)計(jì)學(xué)意義(均P<0.05);24 h的半數(shù)抑制率(IC50)均為25 mg/L。體外遷移試驗(yàn)證實(shí),10、20、25 mg/L芹菜素作用于A375和C8161細(xì)胞24 h后可明顯抑制細(xì)胞遷移(P<0.01)。體外侵襲實(shí)驗(yàn)證實(shí),10、20、25mg/L芹菜素作用于A375和C8161細(xì)胞72 h,細(xì)胞侵襲數(shù)量顯著少于對(duì)照組(P<0.01)。掃描電鏡示,經(jīng)25 mg/L芹菜素作用24 h后,A375和C8161細(xì)胞樹突均變細(xì)長(zhǎng),A375細(xì)胞樹突長(zhǎng)度為(23.30±2.62)μm,與對(duì)照組(12.38±2.27)μm相比差異有統(tǒng)計(jì)學(xué)意義(P<0.01);C8161細(xì)胞樹突長(zhǎng)度為(16.50±1.62)μm,與對(duì)照組(9.36±2.51)μm相比差異亦有統(tǒng)計(jì)學(xué)意義(P<0.01)。10、25 mg/L芹菜素處理24 h后,A375細(xì)胞凋亡率分別為(3.30±0.82)%、(10.00±0.60)%,與對(duì)照組[(0.40±0.07)%、(4.00±0.70)%]相比差異有統(tǒng)計(jì)學(xué)意義(均P<0.01);C8161細(xì)胞凋亡率分別為(13.10±1.45)%、(25.77±2.40)%,與對(duì)照組(7.27±1.31)%相比差異亦有統(tǒng)計(jì)學(xué)意義(均P<0.01)。25 mg/L芹菜素作用于A375和C8161細(xì)胞24 h后,細(xì)胞周期阻滯于G2/M期,其比例分別為(48.70±3.04)%、(31.10±1.90)%,與對(duì)照組[(21.30±0.75)%、(25.06±2.12)%]相比差異有統(tǒng)計(jì)學(xué)意義(均P<0.01)。經(jīng)25 mg/L芹菜素作用24 h后,A375和C8161細(xì)胞凋亡相關(guān)蛋白活化型半胱天冬酶3(Cleaved caspase-3)和多聚腺苷二磷酸-核糖聚合酶裂解片段(Cleaved PARP)表達(dá)均增加,細(xì)胞外信號(hào)調(diào)節(jié)激酶通路均被活化。結(jié)論 芹菜素可抑制人惡性黑素瘤細(xì)胞增殖、遷移、侵襲,誘導(dǎo)細(xì)胞凋亡及周期阻滯,其機(jī)制可能與調(diào)節(jié)ERK信號(hào)通路相關(guān)蛋白的表達(dá)有關(guān)。
芹菜素;黑色素瘤,實(shí)驗(yàn)性;細(xì)胞增殖;細(xì)胞運(yùn)動(dòng);細(xì)胞外信號(hào)調(diào)節(jié)MAP激酶類
由于天然藥物或植物來源的藥物具有副作用小、患者耐受性好、可長(zhǎng)期應(yīng)用等優(yōu)勢(shì),眾多學(xué)者致力于該類藥物輔助治療惡性腫瘤的研究。芹菜素是天然存在的黃酮類化合物,是芹菜中的主要生物活性成分,廣泛存在于多種水果、蔬菜、豆類和茶葉中。據(jù)研究,芹菜素具有抑制離子型谷氨酸受體N-甲基-D-天冬氨酸受體(NMDAR)的作用[1-2]。近年來關(guān)于其抑癌的分子機(jī)制亦獲重大發(fā)現(xiàn)[3-4]。本研究旨在探討芹菜素抑制惡性黑素瘤(惡黑)細(xì)胞增殖、侵襲的作用及其分子機(jī)制。
細(xì)胞系:人黑素瘤A375和C8161細(xì)胞株產(chǎn)自中國(guó)醫(yī)學(xué)科學(xué)院基礎(chǔ)醫(yī)學(xué)研究所北京協(xié)和醫(yī)學(xué)院細(xì)胞資源中心。芹菜素(編號(hào)A0113,CAS登錄號(hào)520-36-5,純度≥98%)產(chǎn)自成都曼斯特生物科技有限公司,用二甲基亞砜(DMSO,美國(guó)Sigma公司)溶解至濃度為40 g/L并于4℃儲(chǔ)存?zhèn)溆谩8咛荄MEM培養(yǎng)基、胰蛋白酶產(chǎn)自美國(guó)Gibco公司,胎牛血清(FBS)產(chǎn)自浙江杭州天杭生物科技有限公司,噻唑藍(lán)(MTT)、TritonX-100、N-甲基-D-天冬氨酸受體拮抗劑MK801產(chǎn)自美國(guó)Sigma公司,不含乙二胺四乙酸(EDTA)的胰蛋白酶產(chǎn)自美國(guó)Hyclone公司,Matrigel產(chǎn)自美國(guó)BD公司,膜聯(lián)蛋白V-異硫氰酸熒光素(Annexin V-FITC)試劑盒產(chǎn)自南京凱基生物科技發(fā)展有限公司,碘化丙錠(PI)、核糖核酸酶(RNase)產(chǎn)自日本TaKaRa公司。抗ERK1/2、phospho-Erk1/2兔抗產(chǎn)自美國(guó)Promega公司,抗poly ADP-ribose polymerase(PARP)和半胱氨酰天冬氨酸蛋白酶3(caspase-3)兔抗產(chǎn)自美國(guó)Cell Signaling Technology公司;抗β肌動(dòng)蛋白鼠抗產(chǎn)自美國(guó)Sigma公司。
1.細(xì)胞培養(yǎng):A375與C8161細(xì)胞均用含10%胎牛血清的DMEM常規(guī)37℃、5%CO2培養(yǎng)箱中培養(yǎng),取對(duì)數(shù)生長(zhǎng)期細(xì)胞用于實(shí)驗(yàn)。配制芹菜素原液于20 mg芹菜素中加入500 μl DMSO。
2.MTT法檢測(cè)不同藥物對(duì)細(xì)胞增殖的影響:將A375與C8161細(xì)胞(1×104/ml)接種于96孔板,每孔200 μl,每組設(shè)3個(gè)復(fù)孔,實(shí)驗(yàn)組每孔加入芹菜素原液,使其終濃度分別為 10、20、30、40、50、60 70 mg/L,對(duì)照組加等量 DMSO,分別于 24、48 、72 96 h加MTT,繼續(xù)于培養(yǎng)箱孵育4 h,棄掉培養(yǎng)液加入200 μl DMSO充分振蕩,于490 nm波長(zhǎng)處用酶標(biāo)儀檢測(cè)各孔吸光度值(A)。增殖抑制率(%)=(1-實(shí)驗(yàn)組A值/對(duì)照組A值)×100%。
3.體外遷移實(shí)驗(yàn)(劃痕法):將A375與C8161細(xì)胞(5 × 105/ml)接種到 24 孔板,每孔 500 μl,于培養(yǎng)箱中孵育24 h,待細(xì)胞生長(zhǎng)至貼壁率70%~80%后用10 μl槍頭垂直孔板輕輕直線刮除細(xì)胞,倒置顯微鏡下觀察,照相。實(shí)驗(yàn)組分別加入含10、20 25 mg/L芹菜素的培養(yǎng)液,對(duì)照組加等量DMSO。繼續(xù)于培養(yǎng)箱孵育24 h后,倒置顯微鏡下觀察,照相計(jì)數(shù)各組劃痕部位遷移來的細(xì)胞數(shù)。
4.體外Matrigel侵襲實(shí)驗(yàn):用24孔Transwell小室,每組3個(gè)復(fù)孔。按照說明書方法進(jìn)行。用DMEM調(diào)整A375和C8161細(xì)胞濃度至1×106/ml。均取100μl細(xì)胞懸液加入小室內(nèi),實(shí)驗(yàn)組細(xì)胞懸液含濃度為10、20、25mg/L的芹菜素,對(duì)照組加等量DMSO,下室按 500 μl/孔加入趨化液(DMEM+10%FBS)。置培養(yǎng)箱中孵育72 h。倒置顯微鏡下觀察穿膜細(xì)胞數(shù),光鏡(×200)下隨機(jī)選取5個(gè)視野(上、下、左、右和中間)照相,計(jì)數(shù)。
5.掃描電鏡觀察細(xì)胞樹突形態(tài)變化:將A375與C8161細(xì)胞均按2×104/ml接種于6 cm培養(yǎng)皿中,經(jīng)25 mg/L芹菜素作用24 h,對(duì)照組加等量DMSO。PBS沖洗貼壁細(xì)胞后用戊二醛固定,PBS沖洗,叔丁醇逐步脫水處理,借助液氮使叔丁醇結(jié)晶,氣化,將樣本剪至所需大小及形狀后貼導(dǎo)電膠置于掃描電鏡樣品托上,Quanta200F型掃描電鏡(美國(guó)FEI公司)觀察、拍照。
6.Annexin-V FITC/PI雙標(biāo)記法檢測(cè)細(xì)胞凋亡率:將A375與C8161細(xì)胞以合適密度接種于6cm培養(yǎng)皿,經(jīng)10、25 mg/L芹菜素作用24 h,對(duì)照組加等量DMSO。用不含EDTA的胰酶消化收集處理后的A375細(xì)胞,PBS洗滌2次,調(diào)整細(xì)胞濃度至1×106/ml,用Annexin-V和PI染色,于室溫下避光15 min,流式細(xì)胞儀檢測(cè)凋亡細(xì)胞。
7.PI單染法檢測(cè)細(xì)胞周期:將A375與C8161細(xì)胞以合適密度接種于6 cm培養(yǎng)皿,經(jīng)10、25 mg/L芹菜素作用24 h,對(duì)照組加等量DMSO。用不含EDTA的胰酶消化收集處理后的A375細(xì)胞,PBS洗滌,用75%預(yù)冷乙醇固定細(xì)胞4 h,分別用500 μl配好的染色液[含480 μl PBS、5 μl P(I5 g/L)、5 μl RNase(10g/L)、10μlTritonX100(10%)]重懸,置 37℃30min后流式細(xì)胞儀檢測(cè)分析周期變化。
8.Western印跡分析:收集經(jīng)25 mg/L芹菜素或DMSO處理24 h的A375與C8161細(xì)胞,加入蛋白裂解液,混勻后冰上裂解30 min,離心后收集上清提取細(xì)胞總蛋白,考馬斯亮藍(lán)法測(cè)定蛋白濃度,均取25 μg蛋白樣品經(jīng)十二烷基硫酸鈉-聚丙烯酰胺凝膠電泳(SDS-PAGE)后,電轉(zhuǎn)至硝酸纖維素膜,5%脫脂牛奶封閉2 h后,加入相應(yīng)一抗4℃孵育過夜,第2天洗膜后加人辣根過氧化物酶標(biāo)記的二抗(1∶5 000)室溫孵育1 h,洗膜后用ECL顯色試劑盒作用1 min,后用Bio-Rad凝膠成像系統(tǒng)成像,用儀器自帶軟件Image Lab(version 4.0)分析條帶灰度。實(shí)驗(yàn)用β肌動(dòng)蛋白做內(nèi)參照。
芹菜素對(duì)A375和C8161細(xì)胞增殖活性的抑制作用在10~40 mg/L濃度范圍0~48 h內(nèi)呈量效關(guān)系(F值分別為 181.96,130.37,均P<0.001),在 0~48 h內(nèi)呈時(shí)效關(guān)系(F值分別為225.14,199.99,均P<0.001),24 h IC50均為25 mg/L,與對(duì)照組相比差異有統(tǒng)計(jì)學(xué)意義(P<0.05);且芹菜素對(duì)A375及C8161細(xì)胞的作用劑量與時(shí)間均有顯著交互效應(yīng)(F值分別為 11.989,37.220,P<0.01),且該交互作用存在濃度及時(shí)間限制。見圖1。
芹菜素實(shí)驗(yàn)組A375和C8161細(xì)胞向劃痕部位遷移的數(shù)量(個(gè))均顯著少于對(duì)照組。每視野下A375細(xì)胞遷移數(shù)量,10 mg/L芹菜素組(3.20±0.84)與20 mg/L組(1.40±0.55)均顯著少于對(duì)照組(50.00±1.58),差異有統(tǒng)計(jì)學(xué)意義(t值分別為 58.50、64.94,均P<0.001);C8161細(xì)胞遷移數(shù)量10 mg/L芹菜素組(11.60±1.52)與 20 mg/L組(3.80±0.84)亦均顯著少于對(duì)照組(81.00±9.35),差異有統(tǒng)計(jì)學(xué)意義(t值分別為16.38、18.38,均P< 0.001)。當(dāng)芹菜素濃度為25 mg/L(IC50),24 h后觀察兩種細(xì)胞株遷移情況,劃痕處均未發(fā)現(xiàn)遷移細(xì)胞。
圖1 不同濃度芹菜素作用不同時(shí)間對(duì)細(xì)胞增殖的抑制作用1A:A375細(xì)胞;1B:C8161細(xì)胞
圖2 掃描電鏡觀察細(xì)胞形態(tài)變化 2A、2C:二甲基亞砜對(duì)照組;2B、2D:25 mg/L芹菜素處理組
芹菜素抑制了A375細(xì)胞和C8161細(xì)胞侵襲。經(jīng)芹菜素處理24h后,每視野下A375細(xì)胞侵襲數(shù)量,10 mg/L芹菜素組(53.00±3.61)顯著少于對(duì)照組(120.80±7.46),差異有統(tǒng)計(jì)學(xué)意義(t=18.29,P<0.01);C8161細(xì)胞侵襲數(shù)量10mg/L芹菜素組(3.00±0.71)顯著少于對(duì)照組(204.00±13.51),差異有統(tǒng)計(jì)學(xué)意義(t=33.22,P<0.01)。當(dāng)芹菜素濃度增加至≥20mg/L,72h后觀察兩種細(xì)胞株侵襲情況,均未發(fā)現(xiàn)穿膜細(xì)胞。
掃描電鏡結(jié)果,經(jīng)25 mg/L芹菜素處理24 h后,A375與C8161細(xì)胞形態(tài)均發(fā)生變化,主要表現(xiàn)為細(xì)胞樹突變細(xì)變長(zhǎng)(圖2)。A375細(xì)胞樹突長(zhǎng)度在25 mg/L芹菜素組為(23.30±2.62)μm,與對(duì)照組(12.38±2.27)μm相比差異有統(tǒng)計(jì)學(xué)意義(P<0.01);C8161細(xì)胞樹突長(zhǎng)度在25 mg/L芹菜素組為(16.50±1.62)μm,與對(duì)照組(9.36±2.51)μm 相比差異有統(tǒng)計(jì)學(xué)意義(P<0.01)。
10、25 mg/L芹菜素處理24 h后,A375細(xì)胞凋亡率分別為(3.30±0.82)%與(10.00±0.60)%,與對(duì)照組[(0.40±0.07)% 和(4.00±0.70)%]相比差異有統(tǒng)計(jì)學(xué)意義(t值分別為 6.11,11.27,均P<0.01);C8161細(xì)胞凋亡率分別為(13.10±1.45)%與(25.77±2.40)%,與對(duì)照組(7.27±1.31)%相比差異有統(tǒng)計(jì)學(xué)意義(t值分別為 5.17,11.73,均P< 0.01)。
表1 25 mg/L芹菜素對(duì)A375和C8161細(xì)胞周期的影響(±s)
表1 25 mg/L芹菜素對(duì)A375和C8161細(xì)胞周期的影響(±s)
注:n=3。25 mg/L芹菜素組誘導(dǎo)了A375和C8161細(xì)胞G2/M期阻滯,與對(duì)照組相比,P<0.05
A375 C8161 G0/G1(%) G2/M(%) G0/G1(%) G2/M(%)對(duì)照組 51.80±3.29 21.30±0.75 45.37±2.61 25.06±2.12 25mg/L芹菜素 32.30±2.86 48.70±3.04 44.63±3.23 31.10±1.90 t值 7.74 15.13 0.31 3.63 P值 0.01 <0.001 >0.05 <0.01組別
25 mg/L芹菜素處理24 h后,可誘導(dǎo)A375細(xì)胞和C8161細(xì)胞周期阻滯在G2/M期。G2/M期A375細(xì)胞和C8161細(xì)胞比例在芹菜素組與對(duì)照組間差異有統(tǒng)計(jì)學(xué)意義(均P<0.05),G0/G1細(xì)胞比例在芹菜素組低于對(duì)照組。見表1。
圖3 Western印跡檢測(cè)凋亡相關(guān)蛋白caspase-3、PARP及總ERK1/2、p-ERK1/2蛋白表達(dá)的影響 3A:A375細(xì)胞株;3B:C8161細(xì)胞株。PARP:多聚腺苷二磷酸-核糖聚合酶;Cleaved PARP:多聚腺苷二磷酸-核糖聚合酶裂解片段;caspase-3:半胱氨酸蛋白酶-3 Cleaved caspase-3:活化型半胱天冬酶-3和(Cleaved PARP);ERK1/2絲裂原活化蛋白激酶1/2;p-ERK1/2:磷酸化絲裂原活化蛋白激酶1/2。1:二甲基亞砜;2:25 mg/L 芹菜素
Western印跡結(jié)果示,經(jīng)25 mg/L芹菜素作用后A375細(xì)胞(圖 3A)及 C8161細(xì)胞(圖 3B)Cleaved caspase-3、Cleaved PARP蛋白表達(dá)均較對(duì)照組明顯增加,而p-ERK1/2蛋白表達(dá)下調(diào),總ERK1/2表達(dá)不變 (圖 3)。當(dāng)設(shè)置組 Cleaved PARP、Cleaved caspase-3、p-ERK的A值為1.00時(shí),其在芹菜素處理組A375細(xì)胞中的相對(duì)A值分別為(2.72±0.17)、(25.00±2.60)、(0.86±0.08);C8161細(xì)胞中A值分別為 (2.26 ± 0.14)、(2.55 ± 0.19)、(0.84 ± 0.09),與對(duì)照組相比差異有統(tǒng)計(jì)學(xué)意義(均P<0.05)。
有研究發(fā)現(xiàn),芹菜素能夠降低cyclin B的表達(dá)及Cdc2的磷酸化并使細(xì)胞周期阻滯在G2-M期,從而有效地抑制胰腺癌細(xì)胞的增殖[5];并且可通過抑制p34(cdc2)激酶,降低p34與cyclin B1蛋白蓄積導(dǎo)致人結(jié)腸癌細(xì)胞的細(xì)胞周期阻滯于G2/M期[6]。另有報(bào)告芹菜素能夠下調(diào)乳腺癌SK-BR-3細(xì)胞中的CDK1、cyclin A及cyclin B的表達(dá),上調(diào)CDK抑制因子p21cip1表達(dá),使SK-BR-3細(xì)胞周期阻滯于G2-M期[7]。對(duì)分別表達(dá)野生型p53和視網(wǎng)膜母細(xì)胞瘤腫瘤抑制蛋白(Rb)的乳腺癌細(xì)胞株MCF-7,以及p53突變與Rb陰性乳腺癌細(xì)胞株MDA-MB-468進(jìn)行研究,發(fā)現(xiàn)芹菜素能夠抑制細(xì)胞增殖、誘導(dǎo)細(xì)胞G2/M期阻滯,同時(shí)伴隨著cyclin B1和CDK1蛋白水平的明顯下降,致使CDK1激酶活力明顯抑制;進(jìn)一步研究發(fā)現(xiàn),芹菜素抑制Rb磷酸化,但不影響cyclin E、CDK2 以及 CDK6 的蛋白水平[8]。在對(duì)突變型p53人結(jié)腸癌細(xì)胞株HT-29和人骨肉瘤細(xì)胞株MG63研究中發(fā)現(xiàn),芹菜素可顯著上調(diào)p21/WAF1蛋白表達(dá),抑制細(xì)胞增殖、導(dǎo)致G2/M期阻滯,且呈量效與時(shí)效關(guān)系。提示芹菜素上調(diào)p21/WAF1蛋白表達(dá)及抑制細(xì)胞增殖不依賴p53途徑[9]。本研究亦發(fā)現(xiàn)芹菜素可誘導(dǎo)黑素瘤A375細(xì)胞及C8161細(xì)胞周期明顯阻滯于G2/M期,因此,有必要對(duì)其具體機(jī)制進(jìn)行深入研究。
促進(jìn)腫瘤細(xì)胞凋亡是抗腫瘤藥物的主要作用機(jī)制。有報(bào)告芹菜素可通過改變Bax/Bcl-2比例促進(jìn)細(xì)胞凋亡,這與細(xì)胞色素C的釋放以及凋亡蛋白酶激活因子-1(Apaf-1)的誘導(dǎo)作用有關(guān),并且導(dǎo)致caspase-3、caspase-9和多聚腺苷二磷酸-核糖聚合酶(PARP)裂解片段的產(chǎn)生[10]。有研究發(fā)現(xiàn),芹菜素可通過促進(jìn)p53的表達(dá),經(jīng)轉(zhuǎn)錄依賴性與非依賴性途徑誘導(dǎo)細(xì)胞凋亡;且細(xì)胞的生存率隨著芹菜素濃度的增加及作用時(shí)間的延長(zhǎng)而逐漸降低[11]。本研究結(jié)果表明,芹菜素可誘導(dǎo)惡黑細(xì)胞凋亡,抑制惡黑ERK信號(hào)通路活化。
我們前期研究發(fā)現(xiàn),谷氨酸受體拮抗劑MK-801及CPCCOEt可導(dǎo)致人惡黑細(xì)胞株WM451細(xì)胞樹突變細(xì)長(zhǎng),其形態(tài)接近正常黑素細(xì)胞,并且可使細(xì)胞骨架蛋白重組、從而抑制WM451細(xì)胞的侵襲、遷移[12-14]。本研究表明,芹菜素亦可改變惡黑細(xì)胞的樹突形態(tài),使樹突由短粗的近三角形變?yōu)殚L(zhǎng)梭狀或細(xì)樹枝狀。推測(cè),芹菜素通過阻斷谷氨酸信號(hào)通路,導(dǎo)致細(xì)胞骨架蛋白的重組及腫瘤細(xì)胞分化,從而影響腫瘤細(xì)胞的遷移與侵襲。
[1]Kudchadkar RR,Smalley KS,Glass LF,et al.Targeted therapy in melanoma[J].Clin Dermatol,2013,31(2):200-208.
[2]Han JH,Kim KJ,Jang HJ,et al.Effects of apigenin on glutamateinduced [Ca](i)increases in cultured rat hippocampal neurons[J].Korean J Physiol Pharmacol,2008,12(2):43-49.
[3]LakshmananA,DoseffAI,RingelMD,etal.Apigeninincombination with Akt inhibition significantly enhances thyrotropin-stimulated radioiodide accumulation in thyroid cells[J].Thyroid,2014,24(5):878-887.
[4]Shao H,Jing K,Mahmoud E,et al.Apigenin sensitizes colon cancer cells to antitumor activity of ABT-263[J].Mol Cancer Ther,2013,12(12):2640-2650.
[5]Ujiki MB,Ding XZ,Salabat MR,et al.Apigenin inhibits pancreatic cancer cell proliferation through G2/M cell cycle arrest[J].Mol Cancer,2006,5:76.
[6]Wang W,Heideman L,Chung CS,et al.Cell-cycle arrest at G2/M and growth inhibition by apigenin in human colon carcinoma cell lines[J].Mol Carcinog,2000,28(2):102-110.
[7]Choi EJ,Kim GH.Apigenin causes G(2)/M arrest associated with the modulation of p21 (Cip1) and Cdc2 and activates p53-dependent apoptosis pathway in human breast cancer SK-BR-3 cells[J].J Nutr Biochemc,2009,20(4):285-290.
[8]Yin F,Giuliano AE,Law RE,et al.Apigenin inhibits growth and induces G2/M arrest by modulating cyclin-CDK regulators and ERK MAP kinase activation in breast carcinoma cells[J].Anticancer Res,2001,21(1A):413-420.
[9]Takagaki N,Sowa Y,Oki T,et al.Apigenin induces cell cycle arrest and p21/WAF1 expression in a p53-independent pathway[J].Int J Oncol,2005,26(1):185-189.
[10]Shukla S,Gupta S.Molecular mechanisms for apigenin-induced cell-cycle arrest and apoptosis of hormone refractory human prostate carcinoma DU145 cells[J].Mol Carcinog,2004,39(2):114-126.
[11]Shukla S,Gupta S.Apigenin-induced prostate cancer cell death is initiated by reactive oxygen species and p53 activation [J].Free Radic Biol Med,2008,44(10):1833-1845.
[12]Song Z,He CD,Liu J,et al.Blocking glutamate-mediated signalling inhibits human melanoma growth and migration[J].Exp Dermatol,2012,21(12):926-931.
[13]李麗麗,單路娟,張媛,等.谷氨酸信號(hào)通路調(diào)控惡性黑素瘤侵襲與增殖的實(shí)驗(yàn)研究[J].中華皮膚科雜志,2011,44(3):186-190.
[14]盧平,周育森,陳萬榮,等.惡性黑素瘤細(xì)胞中的谷氨酸信號(hào)通路及其與細(xì)胞骨架蛋白分子的作用機(jī)制[J].中華皮膚科雜志,2009,42(8):575-578.
Inhibitory effect of apigenin on proliferation and invasion of human malignant melanoma cells
Han Xiaodong*,Meng Songshu,Cheng Wei,Sun Zhe,Ni Jing,Zhang Yunfei,Lin Jingrong,Song Zhiqi.*Department of Dermatology,First Affiliated Hospital of Dalian Medical University,Dalian 116011,China
ObjectiveTo evaluate the inhibitory effect of apigenin on malignant melanomain vitro,and to investigate its mechanisms.MethodsHuman malignant melanoma cell lines A375 and C8161 were divided into test groups and control group separately.Cells in the test groups were treated with apigenin at different concentrations,while cells in the control group were treated with dimethyl sulfoxide,for different durations.Subsequently,methyl thiazolyl tetrazolium (MTT)assay,wound healing assay and Matrigel invasion assay were carried out to estimate cellular proliferative activity,migratory activity and invasive activity,respectively,and scanning electron microscopy(SEM)was used to observe morphology of melanocyte dendrites.Flow cytometry using annexin-V/propidium iodide (PI)staining was performed to detect cell apoptosis,propidium iodide(PI)staining to analyze cell cycle,and Western blot to measure the expressions of proteins related to apoptosis and involved in the extracellular signal-regulated kinase(ERK)signaling pathway.ResultsMTT assay showed significant differences in cellular proliferative activity between the test groups and control group (allP<0.05).The proliferation of A375 and C8161 cells was inhibited by apigenin in a dosedependent manner when the concentration of apigenin was 10-40 mg/L,and in a time-dependent manner when the treatment duration varied from 0 to 48 hours.The half-maximal inhibitory concentration (IC50)of apigenin at 24 hourswas 25 mg/L for both A375 and C8161 cells.Wound healing assay showed that the migration of A375 and C8161 cells was significantly decelerated after 24-hour treatment with apigenin of 10,20 and 25 mg/L compared with the control cells(allP<0.01).Matrigel invasion assay demonstrated that the number of invasive cells was significantly smaller in A375 and C8161 cells treated with apigenin of 10,20 and 25 mg/L for 72 hours than in the control cells(allP<0.01).SEM showed that the dendrits of both A375 and C8161 cells became thinner and longer after treatment with 25 mg/L apigenin for 24 hours,with the length of dendrits being(23.30±2.62)μm and(16.50±1.62)μm respectively,compared to(12.38±2.27)μm and (9.36±2.51)μm respectively in the control groups(bothP<0.01).After treatment with apigenin of 10 and 25 mg/L for 24 hours,a significant increase was observed in apoptosis rate in both A375 cells(3.30%±0.82%vs.0.40%±0.07%,P<0.01;10.00%±0.60%vs.4.00%±0.70%,P<0.01)and C8161 cells(13.10%±1.45%vs.7.27%±1.31%;25.77%±2.40%vs.7.27% ±1.31%;bothP<0.01)compared with the control cells.Both A375 and C8161 cells were arrested in G2/M phase after treatment with 25 mg/L apigenin for 24 hours,with the percentage of cells in G2/M phase being 48.70%±3.04%and 31.10%±1.90%respectively,compared to 21.30%±0.75%and 25.06%±2.12%respectively in the control groups(bothP<0.01).Western blot showed an increase in the expressions of apoptosis-related proteins including cleaved caspase-3 and cleaved poly ADP-ribose polymerase(PARP)with the activation of ERK signaling pathway in both A375 and C8161 cells after 24-hour treatment with 25 mg/L apigenin compared with the control groups.Conclusions Apigenin can inhibit the proliferation,migration and invasion of,but induce apoptosis and cell cycle arrest in human malignant melanoma cells,likely by regulating the expression of ERK signaling pathway-related proteins.
Apigenin;Melanoma,experimental;Cell proliferation;Cell movement;Extracellular signalregulated MAP kinases
Song Zhiqi,Email:szqdalian@163.com
10.3760/cma.j.issn.0412-4030.2015.02.015
國(guó)家自然科學(xué)基金(81472865、81171491);遼寧省自然科學(xué)基金(201102056)
116011大連醫(yī)科大學(xué)附屬第一醫(yī)院皮膚科(韓曉東、孫喆、倪靜、張?jiān)骑w、林景榮、宋智琦);大連醫(yī)科大學(xué)腫瘤干細(xì)胞研究院(孟松樹、程為)
宋智琦,Email:szqdalian@163.com
2014-02-13)
(本文編輯:尚淑賢)